EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Hrishikesh Srinagesh iD, Clayton Jackson, Parveen Shiraz iD, Nikeshan Jeyakumar iD, Mark Hamilton, Emily Egeler, Sharon Mavroukakis, Adam Kuo iD, Juancarlos Cancilla, Bita Sahaf, Neha Agarwal, Alyssa Kanegai und 24 weitere

Blood · 17.10.2024 · 144 (16) · 1689-1698

DOI: 10.1182/blood.2024024952 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Blood, erschienen am 17.10.2024. Verfasst von Hrishikesh Srinagesh und 35 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Stanford University, Stanford, CA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Antigens, CD19, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although chimeric antigen receptor (CAR) T-cell (CAR-T) therapy has revolutionized the treatment of B-cell malignancies, many patients relapse and therefore strategies to improve antitumor immunity are needed. We previously designed a novel autologous bispecific CAR targeting CD19 and CD22 (CAR19-22), which was well tolerated and associated with high response rates but relapse was common. Interleukin-15 (IL15) induces proliferation of diverse immune cells and can augment lymphocyte trafficking. Here, we report the results of a phase 1 clinical trial of the first combination of a novel recombinant polymer-conjugated IL15 receptor agonist (NKTR-255), with CAR19-22, in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Eleven patients were enrolled, 9 of whom successfully received CAR19-22 followed by NKTR-255. There were no dose-limiting toxicities, with transient fever and myelosuppression as the most common possibly related toxicities. We observed favorable efficacy with 8 of 9 patients (89%) achieving measurable residual disease–negative remission. At 12 months, progression-free survival for NKTR-255 was double that of historical controls (67% vs 38%). We performed correlative analyses to investigate the effects of IL15 receptor agonism. Cytokine profiling showed significant increases in IL15 and the chemokines CXCL9 and CXCL10. The increase in chemokines was associated with decreases in absolute lymphocyte counts and CD8+ CAR T cells in the blood and 10-fold increases in cerebrospinal fluid CAR-T cells, suggesting lymphocyte trafficking to tissue. Combining NKTR-255 with CAR19-22 was safe, feasible, and associated with high rates of durable responses. This trial was registered at www.clinicaltrials.gov as #NCT03233854.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveAntigens, CD19Receptors, Chimeric AntigenHumansMaleFemaleAdultMiddle AgedPrecursor B-Cell Lymphoblastic Leukemia-LymphomaInterleukin-15Young AdultSialic Acid Binding Ig-like Lectin 2Aged

Substanzen

Antigens, CD19Receptors, Chimeric AntigenInterleukin-15CD19 molecule, humanSialic Acid Binding Ig-like Lectin 2

Autor:innen und Institutionen

  • Division of Hematology, Stanford University, Stanford, CA.
  • Division of Hematology/Oncology, UT Southwestern, Dallas, TX.
  • Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA.
  • Center for Cancer Cell Therapy, Stanford University, Stanford, CA.
  • Nektar Therapeutics, San Francisco, CA.

ORCID-Profile: Hrishikesh Srinagesh, Parveen Shiraz, Nikeshan Jeyakumar, Adam Kuo, Anne Marijn Kramer, Sally Arai, Michaela Liedtke, Surbhi Sidana, Melody Smith, Steven Feldman, David Miklos, Crystal Mackall, Lori Muffly

Förderung

  • NCI NIH HHS

Zitieren

APA

Srinagesh, H., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A., Kramer, A. M., Arai, S., Bharadwaj, S., Dahiya, S., Hosoya, H., Johnston, L., Kennedy, V., …, & Muffly, L. (2024). A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia. Blood, 144(16), 1689-1698. https://doi.org/10.1182/blood.2024024952

Vancouver

Srinagesh H, Jackson C, Shiraz P, Jeyakumar N, Hamilton M, Egeler E, et al. A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia. Blood. 2024;144(16):1689-1698. doi:10.1182/blood.2024024952

BibTeX
@article{Srinagesh2024,
  author = {Srinagesh, Hrishikesh and Jackson, Clayton and Shiraz, Parveen and Jeyakumar, Nikeshan and Hamilton, Mark and Egeler, Emily and Mavroukakis, Sharon and Kuo, Adam and Cancilla, Juancarlos and Sahaf, Bita and Agarwal, Neha and Kanegai, Alyssa and Kramer, Anne Marijn and Arai, Sally and Bharadwaj, Sushma and Dahiya, Saurabh and Hosoya, Hitomi and Johnston, Laura and Kennedy, Vanessa and Liedtke, Michaela and Lowsky, Robert and Mikkilineni, Lekha and Negrin, Robert and Rezvani, Andrew and Sidana, Surbhi and Shizuru, Judith and Smith, Melody and Weng, Wen-Kai and Feldman, Steven and Frank, Matthew J and Lee, Zachary and Tagliaferri, Mary and Marcondes, A Mario and Miklos, David and Mackall, Crystal and Muffly, Lori},
  title = {A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia},
  journal = {Blood},
  year = {2024},
  volume = {144},
  number = {16},
  pages = {1689--1698},
  doi = {10.1182/blood.2024024952}
}
Kostenlos starten →